Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
asthma
Biotech
Windward breezes toward phase 3 with $165M for TSLP ambitions
The cash infusion is meant to accelerate the development of the company’s lead candidate, a twice-yearly anti-TSLP antibody, into phase 3.
Angus Liu
May 4, 2026 10:31am
AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial
Apr 29, 2026 8:38am
AstraZeneca’s faith in IL-33 blocker pays off with new ph. 3 win
Apr 20, 2026 7:22am
Sanofi bispecific sees respiratory ph. 2 wins, eczema fail
Apr 7, 2026 4:10am
Connect’s Dupixent rival hits the mark in phase 3 eczema trial
Mar 30, 2026 9:32am
Generate plans $425M IPO to bankroll phase 3 asthma trials
Feb 23, 2026 9:42am
